Liquidyne Process Technologies, Inc’s Post

Good news for Cybin!!

Wolfteam Ltd. solves mergers and acquisitions, capital markets, corporate finance, valuations, market risk, AI, modelling in the fast growing, already large, middle income markets of Bulgaria, Central And Eastern Europe. Do contact Wolfteam Ltd. for a free consultation or deals, investing @: petar.posledovich@wolfteamedge.com +359 887 49 68 62 #mergersandacquisitions #capitalmarkets #corporatefinance #valuations #marketrisk #ai #modelling

I would like to discuss the issues on the November 26 Nikkei Shimbun article, "MBOs to Top 1 Trillion Yen in 2023, Taisho Pharmaceutical and Benesse Following in Succession."

Lirentelimab out on failed phase II data; Allakos restructures

Our #MarketUpdate report for the week ending February 9th is now available. Highlights include:    ➡️US equities continued to rally as the S&P 500 broke the 5,000 threshhold for the first time thanks to strong tech earnings and a better-than-expected January jobs report    ➡️Biotech IPOs continue to be active so far in 2024 with two additional companies completing their listings:    ➡️Kyverna Therapeutics raised $319.0M to fund their Phase 2 autoimmune cell therapy candidate    ➡️Metagenomi raised $93.8M to fund their preclinical gene-editing assets targeting a variety of indications    ➡️Last week saw two notable M&A deals announced:    ➡️Novo Holdings made headlines with their $16.5B acquisition of Catalent Pharma Solutions, a deal that will give Novo Nordisk additional manufacturing sites to increase the production of their highly popular obesity and diabetes drugs    ➡️Novartis announced that they had entered into an agreement to acquire MorphoSys AG for $2.9B, further strengthening their oncology pipeline    Read the full update here: https://bit.ly/42zh58M     #HealthcareMarket #oncology #gene #autoimmune #IPO #MarketTrends #BBLSA 

We'll have to watch $LXEO post-IPO performance. After Lexeo, the IPO hopper looks quite barren. IPO pace isn’t expected to pick up until after the annual JP Morgan Healthcare in January. Several industry insiders anticipate about 20 IPOs in the first half of next year. #ipos #capitalmarkets #capitalraising #lifesciences

🌡️ It's July and it's hot. And so is biotech: 💰 Two Massachusetts companies - #MassBioMember Scorpion Therapeutics and Cardurion Pharmaceuticals - just raised $410M in #oncology and #cardiovasculardisease respectively (Boston Business Journal: https://lnkd.in/eViMeruS). 📈 The $XBI is flirting on either side of $100 this week for the first time since March (Endpoints News: https://lnkd.in/ea4RXmy9). 💊 The drugs in these clinical trials (BioPharma Dive: https://lnkd.in/e_UpE-VM) and others could change lives. 📍And Worcester continues to make its strong case to be a #biomanufacturing hub (BBJ: https://lnkd.in/e-Z3hB6k). What's hot in your world?

https://lnkd.in/eViWjw-9 another deal announced as we end the historically low Deals market in 2023 ... should be a great sign once again for a highly anticipated 2024, Bankers and M&A folks are almost expecting a great year in Deals, #investmentbanking #lifesciences #mergersacquisitionsdivestitures #deals

Triveni Raises $92M After Modify, Amagma Merger Thinking about selling your business? Need to find a strategic partner for growth? We are a top investment firm with proven strategies for selling companies and assets in various industries. We also assist company owners in raising capital in various stages of their business growth. Contact me today for a FREE Business Valuation and consultation

#Cannabis investors must be tired of watching $MSOS stagnate. The latest report from KEY Investment Partners sheds some light on the situation and lists 10 #MSOs for consideration. https://lnkd.in/g4FaamT5